Clinical Trial Update: Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of temsirolimus and imatinib mesylate in patients with chronic myeloid leukemia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Gleevec (Imatinib)
• Torisel (Temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia | Phase 1 | Status: TERMINATED